europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

The Business of Biotechnology: Growing for Europe’s tomorrow

15/02/2021
PRESS RELEASE

The Business of Biotechnology: Growing for Europe’s tomorrow
EuropaBio report ‘Measuring the Economic Footprint of the Biotechnology Industry in Europe’

European GDP benefitted by €38.5 bn in 2018, in the recent in-depth study from EuropaBio ‘Measuring the Economic Footprint of the Biotechnology Industry in Europe’. The study looked at the economic impact of the biotechnology industry within the (then) 28 European member states, in terms of gross value added (GVA), employment and trade. Including spill-over effects, that number rises to €78.7bn. The direct contribution adds up to about 1.5% of total industrial GVA within the countries assessed, supported by 223,000 direct jobs rising to over 900,000 with associated employment.

Looking to future economic development, biotechnology continues to mature as an economic force, with an average annual growth rate of 4.1% in 2018, twice as fast as Europe’s information and communication sector (2.0%) and the overall economy (1.9%), making it one of the fastest growing innovative industries in Europe. This reinforces its importance across sectors, both as an enabling technology with economic power in its own right, and also a transformative power for Europe’s future economic recovery and growth. Biotechnology also performed on the global stage for Europe in 2018, with a €22 bn trade surplus in high value goods, reflecting Europe’s innovative strength.

EuropaBio Director General Dr Claire Skentelbery commented “Biotechnology continues to demonstrate that it is a leading sector in European economic development. We don’t need to look far in 2021 to see how innovations are literally saving lives and, at EuropaBio, we also see how it is creating the solutions needed for Green Deal delivery”.

Andrew Topen Chair of the EuropaBio Board added “EuropaBio has been highlighting the significant economic and societal contribution from biotechnology for 25 years. This timely report demonstrates the vital importance of biotech and the importance of a strong ecosystem to foster innovation to the benefit of humanity.”

Join EuropaBio on March 4 at 14:00 CET for the webinar ‘Measuring the Economic Footprint of the Biotechnology Industry in Europe: Landscape and Positions for Development’ where we discuss the report and implications for future economic performance for biotechnology across sectors. About ‘Measuring the Economic Footprint of the Biotechnology Industry in Europe’.

This economic impact study was conducted by WifOR Institute – an independent research institute specialising in impact analysis – in association with the European Association of Bioindustries, EuropaBio. Direct, indirect, and induced effects generated by the biotechnology industry in the EU28 are quantified in accordance with the system of national accounts and using a multiregional input-output model.

Download the full PRESS RELEASE below.

The Business of Biotechnology: Growing for Europe’s tomorrow


Download
2021_02_G_PRESS-RELEASE_EuropaBio_WifOR_The-Economic-Impact-of-BiotechnologyDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
17/01/2023

EuropaBio launches Industry Advisory Group for new Biomanufacturing Platform


Read more
16/01/2023

SwiftPharma joins EuropaBio: pioneering sustainable, scalable and affordable plant-made therapeutic proteins


Read more
19/12/2022

EuropaBio sat down with new member Association of Biotechnological Companies Bioforum, to find out how they champion biotech in central and eastern Europe


Read more

Important links

  • EuropaBio launches SME BioForum in Rare Diseases
  • EuropaBio launches Industry Advisory Group for new Biomanufacturing Platform

Categories in our Newsroom

Search by tags

  • Innovation
  • Excellence
  • Science
  • ATMPs
  • Healthcare Biotech
  • Industrial Biotech
  • Investment
  • EuropaBio
  • EFIB
  • Regulation
  • Rare Diseases
  • COVID-19
  • Members
  • Cancer
  • Patients
  • Patient BioForum
  • Gene & Cell Therapies
  • Accessibility
  • Intellectual Property
  • Pharmaceutical Strategy for Europe

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member